Peanut allergy program

About Desentum

Desentum is a Finnish biotech innovator developing next-generation allergen immunotherapies using its proprietary recombinant hypoallergen technology. The company's lead candidates aim to significantly reduce treatment duration and the risk of severe adverse reactions by modifying allergens to suppress IgE-mediated histamine release. Having completed a rapid €8 million financing round in 2026, Desentum is advancing its lead program for birch pollen allergy through Phase 2 clinical trials. The company seeks to address major limitations of current AIT, positioning itself in the large and growing global allergy treatment market.

About ALK Abello

ALK Abelló's mission is to pioneer allergy immunotherapy solutions that improve and protect the lives of people with allergies globally. The company has achieved a dominant position in the AIT market through its proprietary sublingual tablet technology and a robust commercial portfolio. Its 'Allergy+' strategy for 2024-2028 focuses on expanding its patient reach, advancing a novel pipeline in food allergy and anaphylaxis, and leveraging digital innovation, as evidenced by strong 2025 financials with 15% revenue growth and a 26% EBIT margin.

Therapeutic Areas

Other Peanut allergy Drugs